aged 55, was appointed as our Director on April 23, 2010 and re-designated as a non-executive Director on May 11, 2018. He is the Chairman of our Board and has also been a director of our subsidiary, Hua HK, since August 2010. Since 1994, Mr. Nelsen has served as a co-founder and managing director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, and has played a significant role in the early sourcing, financing and development of more than 30 biopharmaceutical companies. Mr. Nelsen has been serving as a director of Denali Therapeutics, Inc. (stock code: DNLI) since May 2015, Sienna Biopharmaceuticals, Inc. (stock code: SNNA) since August 2015, Syros Pharmaceuticals, Inc. (stock code: SYRS) since August 2012, and Unity Biotechnology, Inc. (stock code: UBX) since November 2011, and previously served as a director of Juno Therapeutics, Inc. (stock code: JUNO) from August 2013 to March 2018, KYTHERA Biopharmaceuticals, Inc. (stock code: KYTH) from January 2006 to December 2014, Agios Pharmaceuticals Inc. (stock code: AGIO) from December 2007 to June 2017, Sage Therapeutics, Inc. (stock code: SAGE) from September 2013 to March 2016, Bellerophon Therapeutics, Inc. (stock code: BLPH) from February 2014 to November 2015, Adolor Corporation (stock code: ADLR) from November 1994 to May 2004, Illumina, Inc. (stock code: ILMN) from June 1998 to August 2006, Fate Therapeutics, Inc. (stock code: FATE) from September 2007 to June 2014, and NeurogesX, Inc. (stock code: NGSX) from July 2000 to July 2013, all of which were companies listed on NASDAQ stock market in the United States. Subsequent to June 29, 2012, NGSX shares were quoted on the Over the Counter Bulletin Board (OTC) in the United States. Mr. Nelsen also previously served as a trustee of Fred Hutchinson Cancer Research Center.
Mr. Nelsen received a Bachelor of Science degree with majors in economics and biology from the University of Puget Sound in the United States in 1985 and an M.B.A. from the University of Chicago in the United States in 1987. Save as disclosed above, Mr. Nelsen is not and has not been a director of any other listed companies in Hong Kong or overseas in the past three years.
aged 56, is our founder and Chief Scientific Officer. He was appointed as a Director on June 4, 2010 and re-designated as an executive Director on May 11, 2018. He has been our Chief Executive Officer since June 4, 2010. Since August 2010 and March 2011, respectively, he has served as a director of Hua HK and Hua Shanghai.
Dr. Chen has over 20 years of experience in the biopharmaceutical industry. He is a pioneer in collaborative innovation in China and has been actively involved in the development of Dorzagliatin (now in its fourth generation) including the years he spent at Roche (from whom we acquired our rights to Dorzagliation in 2011). Dr. Chen joined Roche in 1992 in the United States, focusing on R&D. Dr. Chen held many leadership positions rising to become a member of Roche’s Research Leadership Team. In his last position at Roche before joining Hua, he served as the founding director and chief scientific officer of Roche China R&D Center in Shanghai, China. In that role, Dr. Chen was responsible for development and implementation of Roche China drug discovery strategy, creation of China discovery portfolio, and management of China operations with several drugs from the Roche R&D portfolio during his tenure (including Dorzagliatin) now in the clinical development in China. Since June 2014, Dr. Chen has served as an independent director of Coland Pharmaceutical Co., Ltd (康聯藥業有限公司), listed on Taiwan Stock Exchange (stock code: 4144) and primarily engaged in sales, marketing and distribution of pharmaceutical products and medical devices.
Dr. Chen obtained his Bachelor of Science in Chemistry from Zhengzhou University in July1982, a Master of Science in Chemistry from East China Normal University in November 1985 inShanghai and a Ph.D. in Organic Chemistry in August 1992 from Iowa State University in the UnitedStates. He is an inventor of 35 granted patents and has authored 58 scientific publications. SinceSeptember 2007, Dr. Chen has served as an adjunct professor at Tonji University in Shanghai. In 2001,Dr. Chen served as the President of the Sino-American Pharmaceutical Professionals Association(SAPA).
Mr. George Lin, J.D., a healthcare veteran brings with him over 20 years of investment banking and legal experience working with numerous private and public companies globally. Prior to joining Hua Medicine, he was Asia Pacific Head of Consumer, Retail and Healthcare Investment Banking and Head of Hong Kong and Taiwan Investment Banking for Bank of America Merrill Lynch based in Hong Kong. As an investment banker and corporate lawyer focused on healthcare, retail and the consumer sectors, Mr. Lin was previously based in Los Angeles and San Francisco before moving to Hong Kong in 2007. His experience entails IPOs, debt and equity financings and M&As for leading companies in Asia, the United States and Europe. In the last 10 years alone, Mr. Lin has led M&A transactions valued (in aggregate) in excess of US$20 billion and raised financings valued (in aggregate) at over US$40 billion. Since April 2018, Mr. Lin has served as a member of the Biotech Advisory Panel of the Hong Kong Stock Exchange. Prior to Bank of America Merrill Lynch, Mr. Lin also worked at Credit Suisse as an investment banker in their Hong Kong, San Francisco and Los Angeles offices, and at O'Melveny & Myers LLP as a corporate attorney in their Los Angeles Office. Mr. Lin received a Bachelor of Sciences degree in Biological Sciences from the University of California at Davis and a Juris Doctor degree from The University of Chicago Law School.
aged 55, was appointed as our Director on January 6, 2015 and re-designated as a non-executive Director on May 11, 2018. He has also been a director of our subsidiaries, Hua HK and Hua Shanghai, since January 2015 and April 2016 respectively. Dr. Lian Yong Chen is currently the founding managing partner and CEO of 6 Dimensions Capital. He has over 20 years of experience in the life sciences industry in China and the United States as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He was the founder and managing partner at Frontline BioVentures and a partner at FIL Capital Management (Hong Kong) Limited in Asia from May 2008 to March 2014. He is a member of the Expert Review Panel for the PRC Government’s Thousand Talents Program.
He served as a director of Shanghai Hile Bio-Pharmaceutical Co. Ltd., a company listed on the Shanghai Stock Exchange (stock code: 603718) from December 2014 to December 2017. Save as disclosed above, Dr. Lian Yong Chen is not and has not been a director of any other listed companies in Hong Kong or overseas in the past three years.
Dr. Lian Yong Chen conducted postdoctoral research at the Massachusetts Institute of Technology after obtaining his Ph.D. degree in Chemistry (with top honor) from the University of Louvain, Louvain-La-Neuve in Belgium in July 1991. He obtained his Bachelor of Science degree in Chemistry from Peking University in June 1984.
aged 70, was appointed as independent non-executive Director on [●] (effective from the Listing Date). Mr. Keller is primarily responsible for supervising and providing independent judgment to our Board.
Since May 2017, Mr. Keller has served as an independent non-executive director on the board of WuXi Biologics, a company primarily engaged in biologics services provision and listed on the main board of the Stock Exchange (stock code: 2269). Since December 2010, he holds directorship at Coland Pharmaceutical Co., Ltd., a company listed on the Taiwan Stock Exchange (stock code: 4144). From September 2014 to December 2015, Mr. Keller served as an independent director of WuXi PharmaTech, a biopharmaceutical company formerly listed on the New York Stock Exchange during the same period. Between 1974 to 2003, Mr. Keller served in various positions at the Roche Group, including as the general manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. He has been a vice chairman of the Shanghai Association of Enterprises with Foreign Investment, a senior consultant to the Shanghai Foreign Investment Development Board, and the deputy general manager of Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. Mr. Keller previously held directorships in biopharmaceutical companies including Alexion Pharmaceuticals, Inc., a company listed on NASDAQ (stock code: ALXN) from December 2009 to May 2015, China Nuokang Pharmaceutical Inc. a company listed on NASDAQ (stock code: NKBP) from August 2008 to December 2011. He has also served as a chairman of HBM Biomed China Partners.
Mr. Keller obtained a Bachelor of Science degrees from the School of Economics and Business Administration in Switzerland in July 1972. Save as disclosed above, Mr. Keller is not and has not been a director of any other listed companies in Hong Kong or overseas in the past three years.
aged 54, was appointed as an independent non-executive Director on [●] (effective from the Listing Date). Mr. Liu is the chairman and chief executive officer of New Peak Group, a digital and mobile healthcare platform operator in China. Mr. Liu was a co-founder and chief executive officer of Yihaodian. Before establishing Yihaodian in 2008, Mr. Liu was a co-president of Dell (China) Company Limited from 2006 to 2007. He has been an independent director of Autohome Inc. since January 12, 2015.
Mr. Liu received his Master of International Business Administration degree from Flinders University in Australia in 1998. Save as disclosed above, Mr. Liu is not and has not been a director of any other listed companies in Hong Kong or overseas in the past three years.
aged 65, was appointed as an independent non-executiveDirector on [●] (effective from the Listing Date). Mr. Kwauk is primarily responsible for supervisingand providing independent judgment to our Board.
Mr. Kwauk has been serving as an independent director at Alibaba Group Holding Limited, acompany primarily engaged in internet commerce services and listed on the New York Stock Exchange(stock code: BABA), since September 2014, and is currently the chairman of the audit committee ofAlibaba Group Holding Limited. He previously served as an independent non-executive director andchairman of the audit committee of Alibaba.com Limited, a subsidiary of Alibaba Group HoldingLimited which was listed on the SEHK, from October 2007 to July 2012. Mr. Kwauk is also currentlya senior adviser of Motorola Solutions (China) Co., Ltd., a software and services company primarilyengaged in provision of data communications and telecommunications equipment, and serves as anindependent non-executive director of Sinosoft Technology Group Limited, a software and servicescompany listed on the Stock Exchange (stock code: 1297), and WuXi Biologics (Cayman) Inc., acompany primarily engaged in biologics services provision and listed on the Stock Exchange (stockcode: 2269), for both of which Mr. Kwauk is also the chairman of their audit committees.
From June 2014 to August 2016, he served as an independent non-executive director and thechairman of the audit committee of China Fordoo Holding Limited, a menswear design andmanufacturing company listed on the main board of the Stock Exchange (stock code: 2399), and hasbeen responsible for providing independent judgment to the board of the company. From August 2014to December 2015, Mr. Kwauk also served as an independent director of WuXi PharmaTech, abiopharmaceutical company formerly listed on the New York Stock Exchange during the same period.Mr. Kwauk was a vice president of Motorola Solutions, Inc., data communications andtelecommunications equipment provider, and its director of corporate strategic finance and tax forAsia Pacific from 2003 to 2012. Mr. Kwauk served with KPMG from 1977 to 2002 and held a numberof senior positions, including the general manager of KPMG’s joint venture accounting firm inBeijing, the managing partner in KPMG’s Shanghai office and a partner in KPMG’s Hong KongOffice.
Mr. Kwauk has been a member of the Hong Kong Institute of Certified Public Accountants sinceMarch 1983. He received a bachelor’s degree in science and a licentiate’s degree in accounting fromthe University of British Columbia in Canada in April 1975 and April 1977 respectively.
Save as disclosed above, Mr. Kwauk is not and has not been a director of any other listedcompanies in Hong Kong or overseas in the past three years.
Mr. Tsui has over 21 years of experience in finance and administration, corporate and strategic planning, information technology and human resources management. He served at various positions, including the chief executive of the Stock Exchange from February 1997 to August 2000, the chief operating officer of Hong Kong Exchanges and Clearing Limited from March 2000 to August 2000 and the chairman of Hong Kong Securities Institute from November 1998 to December 2004. Mr. Tsui was the chairman and director of WAG Worldsec Corporate Finance Limited, a private professional consulting services and financial solutions company from February 2006 to June 2016, and presently serves as a director to WAG Worldsec Management Consultancy Limited.
Mr. Tsui is an independent non-executive director of a number of companies listed in Hong Kong, namely, COSCO Shipping International (Hong Kong) Co., Ltd., (stock code: 517) since February 2004, Pacific Online Limited (stock code: 543) since November 2007, Summit Ascent Holdings Limited (stock code: 102) since March 2011, Kangda International Environmental Company Limited (stock code: 6136) since October 2013 and DTXS Silk Road Investment Holdings Company Limited (stock code: 620) since December 2015. He also serves as independent director of NASDAQ listed companies, ATA Inc. (stock code: ATAI) since January 2008 and Melco Resorts & Entertainment Limited (stock code: MLCO) since December 2006 as well as Melco Resorts and Entertainment (Philippines) Corporation (stock code: MRP), a company listed on the Philippine Stock Exchange, since December 2012. Mr. Tsui is also an independent non-executive director of Industrial & Commercial Bank of China (Asia) Limited, a company previously listed in Hong Kong, since August 2000. He also served as independent non-executive directors in various other Hong Kong listed companies, including China Power International Development Limited (stock code: 2380) from March 2004 to December 2016 and China Oilfield Services Limited (stock code: 2883) from June 2009 to June 2015. Save as disclosed above, Mr. Tsui is not and has not been a director of any other listed companies in Hong Kong or overseas in the past three years.
Mr. Tsui graduated from the University of Tennessee in the United States, with a bachelor degree in science in industrial engineering in June 1975 and a master degree in engineering in June 1976. He completed the programme for senior managers in government at the John F. Kennedy School of Government at Harvard University in the United States in August 1993.
Robert Taylor NELSEN
Scope of authority
William Robert KELLER
Walter Teh-Ming KWAUK
Lian Yong CHEN
Robert Taylor NELSEN
William Robert KELLER
Scope of authority
Yiu Wa Alec TSUI